Other aspects to be considered prior to initiation of angiotensin-II infusion is the need for central venous access, as it has the potential to cause severe vasoconstriction of the peripheral vessels and the concurrent deep vein thrombosis prophylaxis due to increased risk of both arterial and venous thromboembolic events [16]. This evidence concerns the gene AGT and deep vein thrombosis.